LABELS · 1203ca7f-080b-4c49-e063-6294a90a90e0

SOLU-CORTEF

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-02-22
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

Full extracted label fields

application numbers

NDA009866

boxed warning exact

brand names

SOLU-CORTEF

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74f84173-a43f-7788-e053-2991aa0a8fb2

generic names

SOLU-CORTEF

1203ca7f-080b-4c49-e063-6294a90a90e0

indications and usage exact

INDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

indications and usage tables exact

is original packager

manufacturer names

HF Acquisition Co. LLC, DBA HealthFirst

matched search terms

cancer
lymphomas
tumor

package ndcs

51662-1261-1
51662-1261-2
51662-1261-3

product ndcs

51662-1261

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAMUSCULAR
INTRAVENOUS

rxcuis

238755

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 776
end exclusive: true
exact text: INDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or s
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 0

current approval status

not_reconciled

duplicate text group

dup-520f0a248519288a0131

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-901149e24273acae4972

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

end: 272
end exclusive: true
exact text: is indicated
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 260

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 576
end exclusive: true
exact text: INDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 943
end exclusive: true
exact text: ate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where ap
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 377

current approval status

not_reconciled

duplicate text group

dup-fe1060c007fa7f441b3e

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-efa138acdf2276c5263f

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 743
end exclusive: true
exact text: Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 577

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1326
end exclusive: true
exact text: sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemoly
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 544

current approval status

not_reconciled

duplicate text group

dup-2fb9f910bb61658cf84e

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-bc9b70ddc9c4166bc516

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1126
end exclusive: true
exact text: Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 744

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1475
end exclusive: true
exact text: ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administr
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 927

current approval status

not_reconciled

duplicate text group

dup-053d379ef60ed60cefdb

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-96ec22485d6dfe126035

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1275
end exclusive: true
exact text: Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1127

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · risk or warning

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1803
end exclusive: true
exact text: ssociated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemothe
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1076

current approval status

not_reconciled

duplicate text group

dup-e9c9164b6303404c2fc5

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-054388570ebec4abdc13

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

context exact
nd Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administrat
kind
age
polarity
not_inferred
span
end
1452
end exclusive
true
exact text
adults
label id
1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start
1446

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1603
end exclusive: true
exact text: Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1276

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2008
end exclusive: true
exact text: ), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumo
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1404

current approval status

not_reconciled

duplicate text group

dup-2c7a4ea822a6a2634f54

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-51f3700223ea0862f1e8

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1808
end exclusive: true
exact text: Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1604

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2086
end exclusive: true
exact text: llaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocul
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1609

current approval status

not_reconciled

duplicate text group

dup-5d8a89e66ead762070b3

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-4b312a32ef924ebb9568

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1886
end exclusive: true
exact text: Neoplastic diseases For the palliative management of leukemias and lymphomas.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1809

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2225
end exclusive: true
exact text: ningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopa
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1687

current approval status

not_reconciled

duplicate text group

dup-747864cafd4d398a0c05

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-db1c9c7805d3d0183ab7

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
kind
biomarker
polarity
not_inferred
span
end
2009
end exclusive
true
exact text
metastatic brain tumor
label id
1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start
1987
context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
kind
stage_or_setting
polarity
not_inferred
span
end
2009
end exclusive
true
exact text
metastatic brain tumor
label id
1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start
1987

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2025
end exclusive: true
exact text: Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1887

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2353
end exclusive: true
exact text: es For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmo
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1826

current approval status

not_reconciled

duplicate text group

dup-3a741948690bae72e39d

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-751b044080a0c07c27b7

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2153
end exclusive: true
exact text: Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 2026

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2485
end exclusive: true
exact text: edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptoma
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 1954

current approval status

not_reconciled

duplicate text group

dup-3436a3d9cd2a1d37d487

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-19877989b29f038078ac

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2285
end exclusive: true
exact text: Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 2154

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2701
end exclusive: true
exact text: ar inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spon
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 2086

current approval status

not_reconciled

duplicate text group

dup-021fa373d64dabbdfe95

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-29bda0f9e27115def4e7

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2501
end exclusive: true
exact text: Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 2286

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2957
end exclusive: true
exact text: ases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 2302

current approval status

not_reconciled

duplicate text group

dup-669ff02e54b4e6b4de28

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-af483761f279b3a4ba04

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2851
end exclusive: true
exact text: Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 2502

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA009866

brand names

SOLU-CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2957
end exclusive: true
exact text: hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 2652

current approval status

not_reconciled

duplicate text group

dup-fc04b5f796453987f505

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-CORTEF

ind-span-9fc4c53dd929d390252b

label id

1203ca7f-080b-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2957
end exclusive: true
exact text: For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 1203ca7f-080b-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 108fa80f94d1e5efa6c1a3ceb0b794feb304a95568d2779c7e6b9dd320563099
start: 2852

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080b-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74f84173-a43f-7788-e053-2991aa0a8fb2

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice